Clinical Trial Update: HAIC Sequential TAE Combined With Lenvatinib and Tislelizumab in Unresectable HCC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating HAIC sequential transarterial embolization with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Guangxi Medical University | Conditions: Liver Cancer | Phase 2 | Status: COMPLETED